# Adjuvant FEC Versus EP in Breast Cancer (MIG5)

> **NCT02450058** · PHASE3 · COMPLETED · sponsor: **IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy** · enrollment: 1055 (actual)

## Conditions studied

- Breast Cancer
- Chemotherapy, Adjuvant

## Interventions

- **DRUG:** 5-fluorouracil
- **DRUG:** epirubicin
- **DRUG:** cyclophosphamide
- **DRUG:** epirubicin
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT02450058
- **Lead sponsor:** IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 1055 (ACTUAL)
- **Last updated:** 2015-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02450058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02450058, "Adjuvant FEC Versus EP in Breast Cancer (MIG5)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02450058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*